Neutralizing antibodies reduce the efficacy of βIFN during treatment of multiple sclerosis

Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

1996 • 2,410 citations

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1998 • 2,049 citations

Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

1993 • 2,032 citations

Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

1993 • 1,908 citations

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

1965 • 1,402 citations

PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS

2001 • 563 citations

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS

2001 • 471 citations

Randomized controlled trial of interferon- beta-1a in secondary progressive MS

2001 • 468 citations

Randomized controlled trial of interferon-beta-1a in secondary progressive MS

2001 • 461 citations

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

2003 • 370 citations

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b

1996 • 361 citations

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis

1998 • 332 citations

A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS

2002 • 224 citations

Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients

2003 • 173 citations

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory

2002 • 149 citations

[74] Quantitation of neutralization of interferon by antibody

1986 • 127 citations

Energy Expenditure, Energy Intake and Prevalence of Obesity after Therapy for Acute Lymphoblastic Leukemia during Childhood

2000 • 110 citations

Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b

2003 • 108 citations

Interferon β neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations

2000 • 96 citations

Evaluation of bioavailability of three types of IFNβ in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification

2001 • 88 citations

Neutralizing antibodies reduce MxA protein induction in interferon- beta-1a-treated MS patients

2002 • 78 citations

Development of Neutralizing Antibodies in Patients with Relapsing-Remitting Multiple Sclerosis Treated with IFN-β1a

1998 • 75 citations

Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS

2000 • 67 citations

Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b

1999 • 63 citations

Neutralizing and Binding Antibodies to IFN-β: Relative Frequency in Relapsing-Remitting Multiple Sclerosis Patients Treated with Different IFN-βPreparations

2002 • 53 citations

Deleted Work

1955 • 0 citations